Case Control Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. May 16, 2023; 15(5): 376-385
Published online May 16, 2023. doi: 10.4253/wjge.v15.i5.376
Effect of modified ShengYangYiwei decoction on painless gastroscopy and gastrointestinal and immune function in gastric cancer patients
Sui-Cai Mi, Ling-Yan Wu, Zheng-Jin Xu, Li-Yan Zheng, Jian-Wen Luo
Sui-Cai Mi, Jian-Wen Luo, Department of Oncology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China
Ling-Yan Wu, Zheng-Jin Xu, Department of Nephropathy, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China
Li-Yan Zheng, Department of Anesthesiology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, Fujian Province, China
Author contributions: Mi SC, Wu LY, and Zheng LY performed the research; Mi SC, and the research; Mi SC designed the research study; Luo JW and Xu ZJ contributed collection and assembly of data; Zheng LY and Wu LY analysed the data; Zheng LY and Wu LY analysed the data; Mi SC and Wu LY wrote the pape.
Supported by Xiamen Municipal Science and Technology Bureau Municipal Medical and Health Guidance Project, No. 3502Z20224ZD1169; Joint project of Natural Science Foundation of Xiamen Municipal Bureau of Science and Technology, No. 3502Z20227368; and The Sixth Batch of Chinese Medicine Reserve Talent Training Project in Xiamen (Xiamen Municipal Health Commission Traditional Chinese Medicine), No. [2022] No. 136.
Institutional review board statement: This study was approved by the Institutional Review Board of Xiamen Hospital of Traditional Chinese Medicine (approval No: 20211129).
Informed consent statement: Informed written consent was obtained from the patient for publication of this study.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest with this work.
Data sharing statement: All data during the study period are included in the public database.
STROBE statement: he authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ling-Yan Wu, MMed, Deputy Director, Department of Nephropathy, Xiamen Hospital of Traditional Chinese Medicine, No. 1739 Xianyue Road, Huli District, Xiamen 361000, Fujian Province, China. 418569189@qq.com
Received: December 6, 2022
Peer-review started: December 6, 2022
First decision: February 28, 2023
Revised: March 7, 2023
Accepted: April 12, 2023
Article in press: April 12, 2023
Published online: May 16, 2023
Abstract
BACKGROUND

Painless gastroenteroscopy is a widely developed diagnostic and treatment technology in clinical practice. It is of great significance in the clinical diagnosis, treatment, follow-up review and other aspects of gastric cancer patients. The application of anesthesia techniques during manipulation can be effective in reducing patient fear and discomfort. In clinical work, the adverse drug reactions of anesthesia regimens and the risk of serious adverse drug reactions are increased with the increase in propofol application dose application dose; the application of opioid drugs often causes gastrointestinal reactions, such as nausea, vomiting and delayed gastrointestinal function recovery, after examination. These adverse effects can seriously affect the quality of life of patients.

AIM

To observe the effect of modified ShengYangYiwei decoction on gastrointestinal function, related complications and immune function in patients with gastric cancer during and after painless gastroscopy.

METHODS

A total of 106 patients with gastric cancer, who were selected from January 2022 to September 2022 in Xiamen Traditional Chinese Medicine Hospital for painless gastroscopy, were randomly divided into a treatment group (n = 56) and a control group (n = 50). Before the examination, all patients fasted for 8 h, provided their health education, and confirmed if there were contraindications to anesthesia and gastroscopy. During the examination, the patients were placed in the left decubitus position, the patients were given oxygen through a nasal catheter (6 L/min), the welling needle was opened for the venous channel, and a multifunction detector was connected for monitoring electrocardiogram, oxygen saturation, blood pressure, etc. Naporphl and propofol propofol protocols were used for routine anesthesia. Before anesthesia administration, the patients underwent several deep breathing exercises, received intravenous nalbuphine [0.nalbuphine (0.025 mg/kg)], followed by intravenous propofol [1.propofol (1.5 mg/kg)] until the palpebral reflex disappeared, and after no response, gastroscopy was performed. If palpebral reflex disappeared, and after no response, gastroscopy was performed. If any patient developed movement, frowning, or hemodynamic changes during the operation (heart rate changes during the operation (heart rate increased to > 20 beats/min, systolic blood pressure increased to > 20% of the base value), additional propofol [0.propofol (0.5 mg/kg)] was added until the patient was sedated again. The patients in the treatment group began to take the preventive intervention of Modified ShengYangYiwei decoction one week before the examination, while the patients in the control group received routine gastrointestinal endoscopy. The patients in the two groups were examined by conventional painless gastroscopy, and the characteristics of the painless gastroscopies of the patients in the two groups were recorded and compared. These characteristics included the total dosage of propofol during the examination, the incidence of complications during the operation, the time of patients' awakening, the time of independent activities, and the gastrointestinal function of the patients after examination, such as the incidence of reactions such as malignant vomiting, abdominal distension and abdominal pain, as well as the differences in the levels of various immunological indicators and inflammatory factors before anesthesia induction (T0), after conscious extubation (T1) and 24 h after surgery (T2).

RESULTS

There was no difference in the patients’ general information, American Society of Anesthesiologist classification or operation time between the two groups before treatment. In terms of painless gastroscopy, the total dosage of propofol in the treatment group was lower than that in the control group (P < 0.05), and the time of awakening and autonomous activity was significantly faster than that in the control group (P < 0.05). During the examination, the incidence of hypoxemia, hypotension and hiccups in the treatment group was significantly lower than that in the control group (P < 0.01). In terms of gastrointestinal function, the incidences of nausea, vomiting, abdominal distension and abdominal pain in the treatment group after examination were significantly lower than those in the control group (P < 0.01). In terms of immune function, in both groups, the number of CD4+ and CD8+ cells decreased significantly (P < 0.05), and the number of natural killer cells increased significantly (P < 0.05) at T1 and T2, compared with T0. The number of CD4+ and CD8+ cells in the treatment group at the T1 and T2 time points was higher than that in the control group (P < 0.05), while the number of natural killer cells was lower than that in the control group (P < 0.05). In terms of inflammatory factors, compared with T0, the levels of interleukin (IL) -6 and tumor necrosis factor-alpha in patients in the two groups at T1 and T2 increased significantly and then decreased (P < 0.05). The level of IL-6 at T1 and T2 in the treatment group was lower than that in the control group (P < 0.05).

CONCLUSION

The preoperative use of modified ShengYangYiwei decoction can optimize the anesthesia program during painless gastroscopy, improve the gastrointestinal function of patients after the operation, reduce the occurrence of examination-related complications.

Keywords: Modified ShengYangYiwei decoction, Gastric cancer patients, Painless gastroscope, Gastrointestinal function

Core Tip: The preoperative use of modified ShengYangYiwei decoction can optimize the anesthesia program during painless gastroscopy, significantly reduce the total dose of propofol during the examination without affecting the quality of the examination, thereby shortening the time of awakening and independent activity, and reducing the occurrence of hypoxemia, hypotension and hiccup during the examination; It improves the gastrointestinal function of patients after operation, reduces the incidence of nausea, vomiting, abdominal distension, abdominal pain and other complications of patients, reduces the inhibition of opioids on the immune system of the body, reduces the inflammatory reaction of patients, is beneficial to the development of painless gastroscopy for gastric cancer patients in clinical practice, reduces the occurrence of examination related complications, and improves the compliance and tolerance of treatment.